Last week it was curing bacterial lung infections and preventing implant rejection. Kamada’s latest trial of its Alpha-1 Antitrypsin (AAT) protein shows that it can halt the progression of juvenile diabetes. Remember, AAT is the active ingredient in Kamada’s Glassia … Continue reading →

Israeli biotech Kamada announced positive results in pre-clinical trials of its Alpha-1 Antitrypsin (AAT) protein. AAT has potential for treating bacterial lung infections and also to prevent implant rejection. AAT is the active ingredient in Kamada’s Glassia , used to … Continue reading →

Israeli biotech Kamada received patent approval for its unique protein proprietary technologies used to produce the company’s intravenous AAT drug. GLASSIA treats chronic emphysema due to congenital deficiency of AAT (Alpha-1 Antitrypsin), an under-diagnosed hereditary condition, which causes irreversible damage … Continue reading →

Israeli biotech Kamada has started producing anti-viper venom serum as a national priority project, financed with NIS 20 million of government money. http://www.globes.co.il/serveen/globes/docview.asp?did=1000677839&fid=1725